Canopy Growth Corporation specializes in the production and sale of cannabis and hemp-based products for both recreational and medical use in Canada. Strengths include a solid liquidity position, with a current ratio of 3.04 and a manageable debt-to-equity ratio of 0.35, indicating financial stability. However, concerns arise from negative margins, with an EBITDA margin of -14.9% and a net margin of -18.0%, reflecting ongoing profitability challenges. The stock's current price of $0.93 suggests a low valuation despite the potential in the growing cannabis market.
Loading financial metrics...
Company posted a loss of $-233.6M over the last year, representing 79.5% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $78.5M over the last year.
Excellent liquidity with current ratio of 3.0x ensures operational stability.
Strong balance sheet with net cash position provides cushion for growth investments.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2027-Q1 (June 30, 2026)